Investor's Business Daily on MSN1d
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 BillionRoche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
BERLIN (Reuters) -Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback